Skip to main content

Advertisement

SpringerLink
Log in

Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Oxaliplatin is a platinum compound that is clinically effective for colorectal cancer (CRC), in combination with 5-fluorouracil (5-FU) and leucovorin (LV), and it is widely used for metastatic disease and for the adjuvant treatment of stage III CRC. With the increasing use of oxaliplatin in Japan, serious adverse events have been experienced other than hematologic and neurologic toxicities.

Methods

In order to clarify the clinical features of allergic reactions to oxaliplatin, we retrospectively investigated CRC patients who had received oxaliplatin-based chemotherapies.

Results

One hundred and twenty-five CRC patients who had been treated with FOLFOX regimens (containing oxaliplatin, 5-FU, and LV) were examined, and 21 patients (17%) were found to have developed allergic reactions. Sixteen patients (13%) had grade 1/2 adverse events, classified according to the common terminology criteria for adverse events (CTC-AE) version 3.0 and 5 (4%) had grade 3/4 adverse events. The allergic reaction appeared after a median number of nine cycles (range, 2–15 cycles). Previous chemotherapy included 5-FU/LV, CPT-11, and S-1. All of the patients with allergic reactions recovered completely when treated with antiallergy drugs. Oxaliplatin was reintroduced in 11 patients, with the use of prophylactic agents; allergic reaction to the reintroduction was not observed in 8 patients and grade 1/2 allergic reactions developed in 3 patients. No correlation was identified between allergic reaction and patients’ background characteristics such as sex, history of allergy, and profile of other adverse events.

Conclusion

Allergic reactions to oxaliplatin remain an important issue for patients being able to safely continue effective chemotherapies; further analysis will be needed to establish methods for the prediction and prophylaxis of such reactions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. De Gramont A, Figer A, Seynour M, et al. (2000) Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947

    PubMed  Google Scholar 

  2. Goldberg RM, Sargent D, Morton RF, et al. (2004) N9741: FOLFOX (oxaliplatin (Oxal)/5-FU/leukovorin (LV)) or reduced dose R-Ifl(CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): final efficacy data from an Intergroup Study. J Clin Oncol 23:275 (Suppl; abstract 3621)

    Google Scholar 

  3. Tvagi P, Grothey A (2006) Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial. Clin Colorectal Cancer 6:261–264

    Article  Google Scholar 

  4. Andre T, Boni C, Mounedji-Boudiaf L, et al. (2004) Multicenter international study of oxaliplatin/5-fluorouracil/leukovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators: oxaliplatin, fluorouracil and leukovorin as adjuvant treatment for colon cancer. N Engl J Med 50:2243–2251

    Google Scholar 

  5. Thomas RR, Quinn MG, Schuler B, et al. (2003) Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 97:2301–2307

    Article  PubMed  Google Scholar 

  6. Siu SW, Chan RT, Au GK (2006) Hypersensitivity reactions to oxaliplatin:experience in a single institute. Ann Oncol 17:2590–2261

    Google Scholar 

  7. Maindrault-Goebel F, Andre T, Tournigand C, et al. (2005) Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer 41:2262–2267

    Article  CAS  PubMed  Google Scholar 

  8. Gowda A, Goel R, Berdzik J, et al. (2004) Hypersensitivity reactions to oxaliplatin: incidence and management. Oncology 18: 1671–1675

    PubMed  Google Scholar 

  9. Brandi G, Pantaleo MA, Galli C, et al. (2003) Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 89:477–481

    Article  CAS  PubMed  Google Scholar 

  10. Shleback AA, Clark PI, Green JA, et al. (1995) Hypersensitivity and cross-reactivity to cisplatin and analogues. Cancer Chemother Pharmacol 35:349–351

    Article  Google Scholar 

  11. Koren C, Yerushalmi R, Katz A, et al. (2002) Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy. Am J Clin Oncol 25:625–626

    Article  PubMed  Google Scholar 

  12. Basu R, Rajkumar A, Datta NR (2002) Anaphylaxis to cisplatin following nine previous uncomplicated cycles. Int J Clin Oncol 7:365–367

    Article  CAS  PubMed  Google Scholar 

  13. Polyzos A, Tsavaris N, Kosmas C, et al. (2001) Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 61:129–133

    Article  CAS  PubMed  Google Scholar 

  14. Zanotti KM, Rybicki LA, Kennedy AW, et al. (2001) Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 19:3126–3129

    CAS  PubMed  Google Scholar 

  15. Stahl M, Koster W, Wikle H (2001) Reaction after oxaliplatin — prevention with corticosteroids? Ann Oncol 12:874

    Article  CAS  PubMed  Google Scholar 

  16. Morgan JS, Adams M, Mason MD (1994) Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma. Eur J Cancer 30:1205–1206

    Article  Google Scholar 

  17. Santini D, Tonini G, Salerno A, et al. (2001) Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol 12:132–133

    Article  CAS  PubMed  Google Scholar 

  18. Newman Taylor AJ, Cullinan P, Lympany PA, et al. (1999) Interaction of HLA phenotype and exposure intensity in sensitization to complex platinum salts. Am J Respir Crit Care Med 160: 435–438

    CAS  PubMed  Google Scholar 

  19. Markmen M, Kennedy A, Webster K, et al. (1999) Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17: 1141–1145

    Google Scholar 

  20. Sliesoraitis S, Chikhale PJ (2005) Carboplatin hypersensitivity. Int J Gynecol Cancer 15:13–18

    Article  CAS  PubMed  Google Scholar 

  21. Lee MY, Yang MH, Liu JH (2007) Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication. Support Care Cancer 15:89–93

    Article  PubMed  Google Scholar 

  22. Mis L, Fernando NH, Hurwitz HI, et al. (2005) Successful desensitization to oxaliplatin. Ann Pharmacother 39:966–969

    Article  PubMed  Google Scholar 

  23. Tournigand C, Cervantes A, Figer A, et al. (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer — a GERCOR study. J Clin Oncol 24:394–400

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan

    Yoshihiro Shibata, Eishi Baba, Yasushi Takii, Hitoshi Kusaba, Koichi Akashi & Shuji Nakano

  2. Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

    Hiroshi Ariyama & Taito Esaki

  3. Department of Medical Oncology, Hamanomachi Hospital, Fukuoka, Japan

    Kenji Mitsugi

  4. Department of Internal Medicine, Sawara Hospital, Fukuoka, Japan

    Tanji Tsuchiya

Authors
  1. Yoshihiro Shibata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroshi Ariyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eishi Baba
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasushi Takii
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Taito Esaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kenji Mitsugi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tanji Tsuchiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hitoshi Kusaba
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Koichi Akashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shuji Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eishi Baba.

About this article

Cite this article

Shibata, Y., Ariyama, H., Baba, E. et al. Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan. Int J Clin Oncol 14, 397–401 (2009). https://doi.org/10.1007/s10147-009-0883-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-009-0883-6

Key words

Search

Navigation